UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of July 2025 (Report No. 3)

 

Commission file number: 001-39957

 

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

 

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

CONTENTS

 

On June 17, 2025, NLS Pharmaceutics Ltd. issued a press release titled: “NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy.” A copy of this press release is furnished herewith as Exhibit 99.1.

 

1

 

EXHIBIT INDEX

 

Exhibit
Number		   Description of Document
99.1   Press release titled: “NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy.”

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NLS Pharmaceutics Ltd.
   
Date: July 17, 2025 By: /s/ Alexander Zwyer
    Name: Alexander Zwyer
    Title: Chief Executive Officer

 

3

 

ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

PRESS RELEASE TITLED: "NLS PHARMACEUTICS HIGHLIGHTS CONTINUED PROGRESS IN ITOL-102 DIABETES PROGRAM AS BIRD FOUNDATION APPROVES ADDITIONAL MILESTONE PAYMENT TO KADIMASTEM AND ITOLERANCE FOR CONTINUED CO-DEVELOPMENT OF TYPE 1 DIABETES CELL THERAPY."